AltMountain

Redmile Group

Larkspur, CA · CRD 143606
Hedge fund manager

Redmile Group is an SEC-registered investment adviser based in Larkspur, CA that reports managing 10 hedge funds on Form ADV. It reports $4.7 billion in regulatory assets under management. Its private funds, of all types, hold $4.6 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +20.3% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +66.1% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.

Regulatory assets under management
$4.7 billionForm ADV Item 5.F
Gross assets of private funds
$4.6 billionAll private fund types, Form ADV
Hedge funds managed
1020 private funds in total
Employees
30Form ADV Item 5.A
Registration
SEC-registered adviserCRD 143606
Latest Form ADV
08/28/2026Disciplinary disclosures: none reported

Estimated 13F portfolio performance

Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.

Estimated from 13F · 2026 YTD+20.3%Through Q2 2026 · S&P 500 +9.5%
Estimated from 13F · 2 years+66.1%Q3 2024 – Q2 2026
S&P 500+37.2%Same quarters, price only
13F holdings$1.5 billion39 positions, 2026-06-30
$75$121$166Q3 2024Q1 2025Q3 2025Q1 202613F est. $166S&P 500 $137
QuarterEst. 13F returnS&P 500
Q2 2026+21.5%+14.8%
Q1 2026-1.0%-4.6%
Q4 2025+34.7%+2.4%
Q3 2025+23.1%+7.8%
Q2 2025+10.8%+10.4%
Q1 2025-23.3%-4.5%
Q4 2024-10.4%+2.1%
Q3 2024+9.5%+5.4%

Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures

Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.

13F holdings as of Sep 30, 2026

All 44 share positions ($1,366,251,642) reported by Redmile Group, LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.

Share of the reported 13F portfolio, ten largest positions

  • Nurix Therapeutics Inc13.71%
  • Krystal Biotech Inc12.84%
  • Scholar Rock Hldg Corp10.73%
  • Stoke Therapeutics Inc7.36%
  • Immunome Inc6.87%
  • Absci Corporation5.26%
  • Electra Therapeutics Inc4.47%
  • Annexon Inc4.42%
  • Neurogene Inc3.18%
  • Regenxbio Inc2.78%
StockValue% of 13F portfolioSharesShares vs prior quarter
Nurix Therapeutics Inc$187,334,72513.71%7,901,085+93.95%
Krystal Biotech Inc$175,486,59112.84%527,684-16.51%
Scholar Rock Hldg Corp$146,601,04410.73%3,033,962-29.62%
Stoke Therapeutics Inc$100,594,7287.36%3,869,028-1.95%
Immunome Inc$93,849,5076.87%4,363,064-11.17%
Absci Corporation$71,850,7305.26%6,671,377-1.01%
Electra Therapeutics Inc$61,097,8284.47%5,430,918New
Annexon Inc$60,396,2574.42%14,278,075+20.29%
Neurogene Inc$43,460,3763.18%1,562,199+10.62%
Regenxbio Inc$38,015,2202.78%5,048,502+15.56%
Shattuck Labs Inc$34,693,2722.54%5,086,990-26.19%
Fate Therapeutics Inc$30,508,8822.23%12,872,946Unchanged
Silence Therapeutics PLC$26,897,5711.97%2,460,894+13.68%
Beam Therapeutics Inc$25,960,5701.90%1,061,782-8.80%
Attovia Therapeutics Inc$19,943,8811.46%1,163,587New
Agomab Therapeutics NV$19,316,5531.41%1,740,230-36.35%
Nuvation Bio Inc$16,973,6501.24%3,031,009Unchanged
Adarx Pharmaceuticals Inc$15,340,7391.12%769,345New
Ideaya Biosciences Inc$14,650,2761.07%381,319-40.44%
Adc Therapeutics SA$14,133,1531.03%11,584,552+0.50%
Solid Biosciences Inc$14,057,5931.03%1,944,342-0.22%
Zymeworks Inc$13,023,9140.95%491,654Unchanged
Obsidian Therapeutics Inc$11,439,2460.84%833,157New
Biomarin Pharmaceutical Inc$11,372,2800.83%189,538-28.52%
Climb Bio Inc$11,177,3890.82%974,489-20.54%
Celldex Therapeutics Inc New$10,428,5660.76%321,770-25.85%
Alx Oncology Hldgs Inc$9,987,5160.73%7,185,263-2.80%
Aura Biosciences Inc$9,749,5680.71%1,552,479-6.85%
Cogent Biosciences Inc$9,497,3240.70%296,606-41.07%
Ceribell Inc$9,433,7110.69%386,786Unchanged
Odyssey Therapeutics Inc$8,321,6120.61%374,510-11.88%
Xenon Pharmaceuticals Inc$7,104,6290.52%191,036-16.71%
Livanova PLC$6,436,0980.47%84,132-9.69%
Atara Biotherapeutics Inc$5,413,2420.40%636,852+44.18%
Insmed Inc$4,896,8340.36%42,902-16.26%
Eupraxia Pharmaceuticals Inc$4,730,9170.35%519,881-14.97%
DBV Technologies S A$4,391,3840.32%373,417-9.02%
Oric Pharmaceuticals Inc$3,944,2450.29%292,817-19.11%
Tcgx Acquisition Corp$3,751,2490.27%299,860New
Prime Medicine Inc$3,503,6570.26%1,146,860-17.47%
Invivyd Inc$1,988,4570.15%2,285,320-12.03%
Ocular Therapeutix Inc$1,871,1270.14%243,954New
Ardelyx Inc$1,791,6350.13%523,870-18.37%
Pliant Therapeutics Inc$833,8960.06%772,126Unchanged

Changes since Jun 30, 2026

Comparing the share counts in the two quarter-end filings: 6 new positions, 1 sold out, 7 increased, 26 reduced and 5 unchanged.

Number of positions (a count, not dollars)

  • New positions6
  • Increased7
  • Unchanged5
  • Reduced26
  • Sold out1

New positions

StockValueShares
Electra Therapeutics Inc$61,097,8285,430,918
Attovia Therapeutics Inc$19,943,8811,163,587
Adarx Pharmaceuticals Inc$15,340,739769,345
Obsidian Therapeutics Inc$11,439,246833,157
Tcgx Acquisition Corp$3,751,249299,860
Ocular Therapeutix Inc$1,871,127243,954

Sold out

StockValue at Jun 30, 2026Shares held then
Establishment Labs Hldgs Inc$7,634,00188,964

Largest increases

StockChange in sharesChangeValue nowShares now
Nurix Therapeutics Inc+3,827,298+93.95%$187,334,7257,901,085
Annexon Inc+2,408,198+20.29%$60,396,25714,278,075
Regenxbio Inc+679,698+15.56%$38,015,2205,048,502
Neurogene Inc+150,000+10.62%$43,460,3761,562,199
Silence Therapeutics PLC+296,117+13.68%$26,897,5712,460,894
Atara Biotherapeutics Inc+195,151+44.18%$5,413,242636,852
Adc Therapeutics SA+57,842+0.50%$14,133,15311,584,552

Largest reductions

StockChange in sharesChangeValue nowShares now
Scholar Rock Hldg Corp-1,277,130-29.62%$146,601,0443,033,962
Krystal Biotech Inc-104,321-16.51%$175,486,591527,684
Shattuck Labs Inc-1,805,043-26.19%$34,693,2725,086,990
Immunome Inc-548,526-11.17%$93,849,5074,363,064
Agomab Therapeutics NV-993,696-36.35%$19,316,5531,740,230
Ideaya Biosciences Inc-258,883-40.44%$14,650,276381,319
Cogent Biosciences Inc-206,715-41.07%$9,497,324296,606
Biomarin Pharmaceutical Inc-75,631-28.52%$11,372,280189,538
Celldex Therapeutics Inc New-112,151-25.85%$10,428,566321,770
Climb Bio Inc-251,841-20.54%$11,177,389974,489
Beam Therapeutics Inc-102,477-8.80%$25,960,5701,061,782
Stoke Therapeutics Inc-76,892-1.95%$100,594,7283,869,028
Xenon Pharmaceuticals Inc-38,338-16.71%$7,104,629191,036
Odyssey Therapeutics Inc-50,490-11.88%$8,321,612374,510
Insmed Inc-8,332-16.26%$4,896,83442,902
Oric Pharmaceuticals Inc-69,193-19.11%$3,944,245292,817
Eupraxia Pharmaceuticals Inc-91,519-14.97%$4,730,917519,881
Prime Medicine Inc-242,772-17.47%$3,503,6571,146,860
Absci Corporation-68,298-1.01%$71,850,7306,671,377
Aura Biosciences Inc-114,188-6.85%$9,749,5681,552,479

Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.

From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures

Large ownership stakes (Schedule 13D and 13G)

CompanyFilingPercent of classSharesFiledSource
AgomAb Therapeutics NV13G amendment3.5%1,740,230Nov 16, 2026SEC.gov ↗
Fate Therapeutics Inc13D amendment14.99%19,164,572Nov 9, 2026SEC.gov ↗
Electra Therapeutics, Inc.13G8.7%5,462,881Sep 28, 2026SEC.gov ↗
Nurix Therapeutics, Inc.13G amendment8.1%8,782,256Aug 14, 2026SEC.gov ↗
Neurogene Inc.13G amendment9.9%1,572,202Aug 14, 2026SEC.gov ↗
Scholar Rock Holding Corporation13G amendment3.6%4,311,092Aug 14, 2026SEC.gov ↗
Atara Biotherapeutics, Inc.13D amendment9.9%950,994Jul 24, 2026SEC.gov ↗
Shattuck Labs, Inc.13D amendment9.9%10,019,421Jul 17, 2026SEC.gov ↗
Annexon, Inc.13G amendment9.9%17,918,459Jul 8, 2026SEC.gov ↗
Stoke Therapeutics, Inc.13G amendment6.7%4,164,120May 15, 2026SEC.gov ↗
Immunome, Inc.13G amendment4.9%5,558,885May 15, 2026SEC.gov ↗
ALX Oncology Holdings Inc.13G amendment6.8%9,214,188May 15, 2026SEC.gov ↗
ADC Therapeutics SA13G amendment9.9%12,717,487Apr 24, 2026SEC.gov ↗
Absci Corporation13D amendment4.9%7,607,449Apr 14, 2026SEC.gov ↗
Zymeworks Inc.13G amendment4.9%3,705,750Nov 14, 2025SEC.gov ↗

A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 16 companies. Source: U.S. Securities and Exchange Commission, EDGAR.

Hedge funds filing Form D (5)

Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.

Private funds reported on Form ADV (18)

Fund
Gross assets
Minimum
Owners
Adviser
Redco II Master Fund, L.P.
Cayman IslandsHedge fund
Gross assets$1.5B
Minimum$10.0M
Owners41
AdviserRedmile Group
Redmile Biopharma Investments III, L.P.
Delaware, United StatesPrivate equity fund
Gross assets$1.2B
Minimum$5.0M
Owners330
AdviserRedmile Group
Redmile Capital Offshore II Master Fund, LTD.
Cayman IslandsHedge fund
Gross assets$962M
Minimum$1.0M
Owners8
AdviserRedmile Group
Redmile Biopharma Investments II, L.P.
Delaware, United StatesVenture capital fund
Gross assets$828M
Minimum$5.0M
Owners138
AdviserRedmile Group
Redmile Capital Offshore Master Fund, LTD.
Cayman IslandsHedge fund
Gross assets$729M
Minimum$5.0M
Owners217
AdviserRedmile Group
Redmile Capital Fund, LP
Delaware, United StatesHedge fund
Gross assets$654M
Minimum$5.0M
Owners348
AdviserRedmile Group
Redmile Strategic Long Only Trading Sub, LTD.
Cayman IslandsHedge fund
Gross assets$286M
Minimum$5.0M
Owners47
AdviserRedmile Group
RAF, L.P.
Cayman IslandsVenture capital fund
Gross assets$261M
Minimum$50.0M
Owners2
AdviserRedmile Group
Redmile Strategic Trading Sub, LTD.
Cayman IslandsHedge fund
Gross assets$212M
Minimum$5.0M
Owners115
AdviserRedmile Group
Redmile Growth Investments I, L.P.
Delaware, United StatesVenture capital fund
Gross assets$157M
Minimum$5.0M
Owners3
AdviserRedmile Group
Redmile Biopharma Investments I, L.P.
Delaware, United StatesVenture capital fund
Gross assets$143M
Minimum$2.0M
Owners80
AdviserRedmile Group
Redco I, L.P.
Delaware, United StatesHedge fund
Gross assets$109M
Minimum$5.0M
Owners52
AdviserRedmile Group
Redmile Private Investments II, L.P.
Delaware, United StatesVenture capital fund
Gross assets$61.6M
Minimum$2.0M
Owners29
AdviserRedmile Group
Redmile Capital Offshore Fund (Erisa), LTD.
Cayman IslandsHedge fund
Gross assets$55.2M
Minimum$5.0M
Owners24
AdviserRedmile Group
RM Special Holdings 4, LLC
Delaware, United StatesPrivate equity fund
Gross assets$44.9M
Minimum$5.0M
Owners10
AdviserRedmile Group
Redmile Private Investments I, L.P.
Delaware, United StatesVenture capital fund
Gross assets$15.9M
Minimum$2.0M
Owners11
AdviserRedmile Group
Redmile Private Investments I Affiliates, L.P.
Delaware, United StatesVenture capital fund
Gross assets$11.9M
Minimum$2.0M
Owners17
AdviserRedmile Group
RM Special Holdings 8, LLC
Delaware, United StatesPrivate equity fund
Gross assets$1.2M
Minimum$5.0M
Owners2
AdviserRedmile Group

As reported in the adviser's Form ADV filed Jul 3, 2024. Funds also listed from Form D are shown above.

From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures⁠​​‌‌‌‌‌‌‌‌​​​​​​​​‌​⁠